Literature DB >> 25016703

Growth differentiation factor 15, ischemia modified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease.

Lie Ying Fan, Zhong Gan Jin, Ming Zong, Qing Zhong Wang, Yi Ju, Li Shan Sun, Yu Ying Gu, Ping Yu, Dai Fu Zhang, Zhong Min Liu.   

Abstract

BACKGROUND: Growth differentiation factor 15 (GDF-15), ischemia modified albumin (IMA) might aid in the early diagnosis and risk stratification of patients with coronary artery disease (CAD), while pregnancy associated plasma protein-A (PAPP-A) can serve as a useful marker of vulnerable plaques and acute coronary syndrome (ACS). We sought to determine serum levels of GDF-15, IMA, PAPP-A and evaluate their diagnostic value in different types of CAD.
METHODS: We detected serum levels of GDF-15, IMA and PAPP-A in 348 patients with CAD and 205 controls. Levels of high-sensitivity C reactive protein, creatine kinase isoenzyme MB, and high-sensitivity cardiac troponin-T, which represent biomarkers of inflammation, damage or necrosis, were also evaluated.
RESULTS: There were significant differences of GDF-15, IMA and PAPP-A in patients with CAD compared with the controls, where GDF-15 seemed to be associated with severity of CAD. GDF-15 demonstrated a sensitivity of 84.0% and specificity of 84.8% for diagnosis of UAP, while the negative predictive value was 87.4%. The sensitivity and specificity, negative predictive value of IMA in the diagnosis of UAP were 70.0%, 69.5%, and 70.0%, respectively. PAPP-A had the lowest sensitivity and negative predictive value compared with other markers.
CONCLUSIONS: GDF-15 demonstrated a significant improvement in earlier prediction and assessment of overall patient risk of UAP comparing to IMA and PAPP-A.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25016703     DOI: 10.7754/clin.lab.2013.130448

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  3 in total

1.  Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Authors:  Yong-Ming Zhou; Ming-Jiang Li; Yan-Li Zhou; Le-Le Ma; Xin Yi
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 2.  GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.

Authors:  Ramu Adela; Sanjay K Banerjee
Journal:  J Diabetes Res       Date:  2015-07-27       Impact factor: 4.011

3.  The Effect of Effort Test on the Levels of Ischemia Modified Albumin, 7-ketocholesterol and Cholestan-3β , 5α , 6β -triol and their Role in the Diagnosis of Coronary Artery Disease.

Authors:  Muhammed Emin Keles; Afshin Samadi; Selen Yilmaz Isikhan; Yusuf Ziya Sener; Ali Sezgin; Emine Keles; Incilay Lay; Uğur Canpolat
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.